APMA Urges CMS to Address Key Flaws in Proposed Diabetic Disease MVP

APMA submitted comments to CMS and Acumen, LLC, pressing for changes to the draft 2027 Diabetic Disease MIPS Value Pathway (MVP) Candidate. While APMA generally supports the development of an additional MVP option, we urged CMS to make substantive changes to ensure the pathway actually reduces burden and allows podiatrists to succeed in MIPS. Specifically, APMA recommended:

• Maintain automatic reweighting of the Promoting Interoperability Performance Category for "small practices" and other small practice bonus opportunities

• Remove the topped-out status and scoring limitations on all quality measures in the MVP

• Add an additional improvement activity options within the Podiatry MVP

• Retire the TPCC measure.

Read this and all past comment letters in full at https://www.apma.org/commentletters. If you have any questions or concerns related to MIPS, please email APMA at [email protected].